找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Advances in Lymphoma Research; Fernando Cabanillas,M. Alma Rodriguez Book 1996 Springer Science+Business Media New York 1996 Grading.cance

[復(fù)制鏈接]
查看: 43566|回復(fù): 46
樓主
發(fā)表于 2025-3-21 19:50:11 | 只看該作者 |倒序瀏覽 |閱讀模式
期刊全稱Advances in Lymphoma Research
影響因子2023Fernando Cabanillas,M. Alma Rodriguez
視頻videohttp://file.papertrans.cn/149/148698/148698.mp4
學(xué)科分類Cancer Treatment and Research
圖書封面Titlebook: Advances in Lymphoma Research;  Fernando Cabanillas,M. Alma Rodriguez Book 1996 Springer Science+Business Media New York 1996 Grading.cance
影響因子Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third- generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that ‘nothing works better than CHOP‘ and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed bec
Pindex Book 1996
The information of publication is updating

書目名稱Advances in Lymphoma Research影響因子(影響力)




書目名稱Advances in Lymphoma Research影響因子(影響力)學(xué)科排名




書目名稱Advances in Lymphoma Research網(wǎng)絡(luò)公開度




書目名稱Advances in Lymphoma Research網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Advances in Lymphoma Research被引頻次




書目名稱Advances in Lymphoma Research被引頻次學(xué)科排名




書目名稱Advances in Lymphoma Research年度引用




書目名稱Advances in Lymphoma Research年度引用學(xué)科排名




書目名稱Advances in Lymphoma Research讀者反饋




書目名稱Advances in Lymphoma Research讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:19:56 | 只看該作者
板凳
發(fā)表于 2025-3-22 03:03:17 | 只看該作者
地板
發(fā)表于 2025-3-22 07:43:32 | 只看該作者
5#
發(fā)表于 2025-3-22 09:42:55 | 只看該作者
Stephen E. Ling M.D.,Pallav N. Shah M.D. variety of indolent B- and T-cell lymphoid malignancies. The activity of 2-CdA has been demonstrated in hairy cell leukemia [1-4], chronic lymphocytic leukemia [5-7], non-Hodgkin’s lymphoma [8-12], cutaneous T-cell lymphoma [13], and the myeloid leukemias [14-16]. 2-CdA gained wide attention in 199
6#
發(fā)表于 2025-3-22 15:05:32 | 只看該作者
https://doi.org/10.1007/978-3-319-47907-1arge series [1]. While the subtypes of Hodgkin’s disease as outlined in the Lukes-Butler classification no longer have a significant impact on survival due to improvements in staging and therapy, 15% to 20% of patients still die of disease [2,3]. The NSHD subtype is the most frequent, and its cytolo
7#
發(fā)表于 2025-3-22 18:32:36 | 只看該作者
Clinical Research Case Descriptionsir variability is manifested at many levels, from the microscopic world of pathology to the macroscopic world of the clinic. The histologic and cytologic spectrum of non-Hodgkin’s lymphoma is broad, ranging from tumors of mature lymphoid cells to tumors composed of highly anaplastic or blastic cells
8#
發(fā)表于 2025-3-22 21:28:31 | 只看該作者
Study Goals, Hypothesis, and Designty for the lymphoma to arise from nodal or extranodal sites, and its capacity to remain localized or to disseminate in the whole body. In order to propose to his (her) patient the best therapeutic options, a physician has to take into account all the prognostic implications of this heterogeneity. Ho
9#
發(fā)表于 2025-3-23 02:15:59 | 只看該作者
Clinician‘s Guide to Mycosis Fungoidesof cure, depending on a number of factors. He described factors that at diagnosis have had prognostic significance for survival. Some of these factors are host dependent, while others are tumor dependent. Relapse of the disease is nearly always a fatal event. In a number of prior series from M.D. An
10#
發(fā)表于 2025-3-23 06:39:41 | 只看該作者
Clinician‘s Guide to Severe Hoardingut the indications of HDC in the treatment of NHL still remains controversial [1,2]. The Consensus Conference on the Indications of HDC, which was held in Lyon in 1993, has concluded that there was no clinical situation in which HDC could be considered as a standard treatment in NHL [1,2].
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-29 01:06
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
德江县| 德阳市| 新竹县| 锡林浩特市| 宜良县| 绥德县| 剑河县| 阿巴嘎旗| 阿拉善盟| 馆陶县| 通州市| 仪陇县| 清新县| 郯城县| 报价| 会东县| 通许县| 抚远县| 中卫市| 嘉鱼县| 都昌县| 丰宁| 乐平市| 金塔县| 通河县| 万源市| 长海县| 东方市| 六盘水市| 宣化县| 永新县| 山阴县| 宜黄县| 桐柏县| 武宣县| 泸水县| 商南县| 赞皇县| 宁武县| 诸暨市| 彩票|